Market Overview

UPDATE: Stifel Nicolaus Raises PT to $40 on Theravance on Improved Risk Profile

Related THRX
Theravance Inc Reports Prelim Tender Offer Results
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan

Stifel Nicolaus reiterated its Buy rating on Theravance (NASDAQ: THRX) and raised its price target from $28 to $40.

Stifel Nicolaus noted, "We believe recently-announced top-line P3 LAMA/LABA data implies a relatively clear regulatory path forward and our physician conversations suggest the utilization of these combined mechanisms of action should gain considerable traction/adoption in those moderate/severe COPD patients whom require prolonged/significant bronchodilation."

Therevance closed at $29.49 on Friday.

Latest Ratings for THRX

May 2015Cowen & Co.DowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014StifelDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!

Partner Center